Grant of Options
The Probiotic To Support Heart Health
ProBiotix Health is a life sciences company that develops probiotic formulations to support cardiometabolic health
Since its creation, ProBiotix has become a global leader in microbiome modulating
probiotics for use in food supplements and nutraceuticals
At the heart of the Company’s mission lies a unique approach; discovering groundbreaking probiotics, ensuring their benefits through solid science, and bringing to market effective finished probiotic-based products for human health across the globe.

Identification
Identification and evolution of ground breaking probiotic strains targeting lifestyle conditions that are prevalent in healthy ageing.

Validation
Scientific validation ensures the probiotic strains stand on a solid foundation of validated safety and efficacy for human health.

Commercialisation
Developing advanced probiotic-based product formulations targeted for cardiometabolic health, ensuring measurable health benefits. Providing business-to-business turn-key or “white label”, probiotic based supplements to organisations worldwide.

LP LDL
Superior Probiotic Strain for Cardiometabolic Health
Independent clinical studies¹ have shown that ProBiotix’s principal identified probiotic strain, LPLDL®, can reduce key cardiovascular risk biomarkers, such as total cholesterol by 36%, LDL by 28%, non-HDL cholesterol by 17% and apolipoprotein B by 28%.
Latest RNS News
Latest Interview
Aquis-listed ProBiotix Health taps into demand for cardiovascular disease treatments
Stephen O'Hara | 23 February 2023
IG UK | Youtube